Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Traws Pharma ( (TRAW) ) just unveiled an update.
On March 31, 2025, Traws Pharma announced its financial results for the year ending December 31, 2024, and highlighted significant progress in its investigational programs. The company reported positive data for its lead product candidate, tivoxavir marboxil, in treating bird flu, and ongoing FDA interactions for potential accelerated approval. Additionally, Traws Pharma completed a successful financing round, securing $20 million to support operations into Q1 2026. The company also announced the retirement of its CEO, Werner Cautreels, with Iain D. Dukes stepping in as Interim CEO.
More about Traws Pharma
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies to address critical threats to human health from respiratory viral diseases. The company’s primary products include tivoxavir marboxil, in development for bird flu, and ratutrelvir, in development for COVID-19.
YTD Price Performance: -72.32%
Average Trading Volume: 105,757
Technical Sentiment Signal: Buy
Current Market Cap: $12.08M
For an in-depth examination of TRAW stock, go to TipRanks’ Stock Analysis page.